Comparison of the capability of GDNF, BDNF, or both, to protect nigrostriatal neurons in a rat model of Parkinson's disease.
about
Phosphodiesterase Inhibition and Regulation of Dopaminergic Frontal and Striatal Functioning: Clinical ImplicationsNeurotrophic factors as a therapeutic target for Parkinson's diseaseNeuroregeneration in neurodegenerative disorders.Enhanced nigrostriatal neuron-specific, long-term expression by using neural-specific promoters in combination with targeted gene transfer by modified helper virus-free HSV-1 vector particles.Viral vectors for neurotrophic factor delivery: a gene therapy approach for neurodegenerative diseases of the CNSGene delivery with viral vectors for cerebrovascular diseases.Zirconium oxide ceramic foam: a promising supporting biomaterial for massive production of glial cell line-derived neurotrophic factorBrain-derived neurotrophic factor suppresses tunicamycin-induced upregulation of CHOP in neurons.Neurotensin-polyplex-mediated brain-derived neurotrophic factor gene delivery into nigral dopamine neurons prevents nigrostriatal degeneration in a rat model of early Parkinson's disease.Intracarotid Infusion of Mesenchymal Stem Cells in an Animal Model of Parkinson's Disease, Focusing on Cell Distribution and Neuroprotective and Behavioral Effects.Trophic factors GDNF and BDNF improve function of retinal sheet transplantsTransgene expression in the striatum following intracerebral injections of DNA nanoparticles encoding for human glial cell line-derived neurotrophic factor.Exercise copes with prolonged stress-induced impairment of spatial memory performance by endoplasmic reticulum stress.Efficient Expression of Igf-1 from Lentiviral Vectors Protects In Vitro but Does Not Mediate Behavioral Recovery of a Parkinsonian Lesion in Rats.Shedding light into the role of BDNF in the pharmacotherapy of Parkinson's disease.HSV-1 amplicon vectors: a promising and versatile tool for gene delivery.Frontiers in the surgical treatment of Parkinson's disease.GDNF therapy for Parkinson's disease.FTY720/Fingolimod Reduces Synucleinopathy and Improves Gut Motility in A53T Mice: CONTRIBUTIONS OF PRO-BRAIN-DERIVED NEUROTROPHIC FACTOR (PRO-BDNF) AND MATURE BDNF.Decreased expression of ErbB4 and tyrosine hydroxylase mRNA and protein in the ventral midbrain of aged rats.Challenges and opportunities in CNS delivery of therapeutics for neurodegenerative diseases.Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson's disease.Delayed transplantation of precursor cell-derived astrocytes provides multiple benefits in a rat model of Parkinsons.Viral vectors for gene delivery to the central nervous system.Revelation in the neuroprotective functions of rasagiline and selegiline: the induction of distinct genes by different mechanisms.Gene therapy for the treatment of Parkinson's disease: the nature of the biologics expands the future indicationsDoes PGC1α/FNDC5/BDNF Elicit the Beneficial Effects of Exercise on Neurodegenerative Disorders?A 16 bp upstream sequence from the rat tyrosine hydroxylase promoter supports long-term expression from a neurofilament promoter, in a helper virus-free HSV-1 vector system.Enhanced efficacy of the CDNF/MANF family by combined intranigral overexpression in the 6-OHDA rat model of Parkinson's disease.Neuroprotective potential of pleiotrophin overexpression in the striatonigral pathway compared with overexpression in both the striatonigral and nigrostriatal pathways.Neurotrophin Signaling and Stem Cells-Implications for Neurodegenerative Diseases and Stem Cell Therapy.Stimulation of the rat subthalamic nucleus is neuroprotective following significant nigral dopamine neuron loss.Electrical stimulation of the dorsal columns of the spinal cord for Parkinson's disease.The vesicular glutamate transporter-1 upstream promoter and first intron each support glutamatergic-specific expression in rat postrhinal cortex.Genetic labeling of both the axons of transduced, glutamatergic neurons in rat postrhinal cortex and their postsynaptic neurons in other neocortical areas by herpes simplex virus vectors that coexpress an axon-targeted β-galactosidase and wheat germAntibody-mediated targeted gene transfer to NMDA NR1-containing neurons in rat neocortex by helper virus-free HSV-1 vector particles containing a chimeric HSV-1 glycoprotein C-staphylococcus A proteinAlginate-matrigel microencapsulated schwann cells for inducible secretion of glial cell line derived neurotrophic factor.Herpes Virus Amplicon Vectors.Role of glial cell derived neurotrophic factor in the protective effect of smilagenin on rat mesencephalic dopaminergic neurons damaged by MPP+.Protection of dopaminergic neurons by electroconvulsive shock in an animal model of Parkinson's disease.
P2860
Q26753116-B5FE5A87-49B9-41F8-9B11-3C7D47DBF3D4Q28273071-E7CAC73C-31B7-45FE-90DC-D1A092BFFC9DQ31020342-CCDADE14-6B0D-4C26-BFC9-2088395A2863Q33327584-57FD2831-81F8-458B-BE91-610EB254AA8EQ33894621-815A3A5A-6CD6-4942-8710-6D71B1C75A20Q33917592-8113C26D-DF74-40B0-B765-3F99A9CBEE36Q34696178-48C2C7FA-FFD2-40AB-93A4-F87277FCDD5DQ34903552-8479D1C6-44F0-4D85-8B25-BE3C20567A92Q35878528-3E691F44-8313-4D09-8017-36D9040FA1DEQ35975405-98EAD440-BA62-4C05-A508-F3391F8666E8Q36042299-CF126F51-84A9-41FE-B297-3169E12D5228Q36128982-016115AC-46DC-41F7-BC0B-74C62D66AA3AQ36218602-C9833016-95FB-4E4B-A5BD-A6B94A50C97EQ36294787-C62CA686-D51E-4697-8074-C54A2CA9053AQ36364388-09E07803-EE77-4D00-9D4D-260959FE6BECQ36897379-61F729EF-EAEF-4D01-AB0C-51785908F3EFQ37174039-05F152C0-5E26-4F52-94A6-3FA2760D1E31Q37203371-6BF46B4B-4982-44E8-9D7B-78B51E89D07FQ37277536-96C26C40-6134-4022-82D3-BF223B85BB53Q37371366-C81767F5-9928-4399-A1A7-EEDAF8095568Q37416147-36BFD040-04B9-4142-A432-879204DE73A6Q37578490-2CA5EF5A-961C-4F47-8FCC-DC5CF86E7C73Q37710820-6C3C3A8A-AA98-4A24-BC3B-CDA1B067DE7AQ37946113-5A6A243A-07E0-4E81-AEDD-75E5973188D6Q38112214-32964891-D614-4FC1-8999-60FA0280C917Q38166648-E4293AD4-E339-4C9F-9167-9E7AA283E0F1Q38649157-9AB12CE3-74C5-4FDC-8FE3-E3A5327D9837Q38669532-7165C14C-765C-40D1-923C-516A6B0AEDE8Q38942851-078A8CBE-53E4-4FFB-A4CF-FB74517605F7Q38997247-93065B77-38B0-49E1-813E-CB1BA0EAAD97Q38999345-259BFF4D-9A05-4787-B636-FF8993E2FF01Q39288979-0FD2C3F3-98FE-4505-AB89-D5A0E996FCD9Q39302042-FAFE01ED-85F7-47C5-8DCE-0872F9EBF5C7Q39617892-A8C111EB-4472-422C-8B08-C8BF07B7D4ABQ39654588-8407DEF2-06EA-4441-9C8E-FA31CAFC636EQ39685068-83DD455F-B356-4B70-9307-E106FDE7C6BBQ39880344-08FD0AE3-CECE-4747-BA92-ED38CCEE6200Q39923388-8A5463E6-162C-4453-AB7C-B8E29C92ECD1Q40009062-8FFD62BC-2621-4486-9A06-3EB54C73F8D0Q40081356-EC053280-CC59-4B22-8709-96B91764184A
P2860
Comparison of the capability of GDNF, BDNF, or both, to protect nigrostriatal neurons in a rat model of Parkinson's disease.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Comparison of the capability o ...... model of Parkinson's disease.
@en
type
label
Comparison of the capability o ...... model of Parkinson's disease.
@en
prefLabel
Comparison of the capability o ...... model of Parkinson's disease.
@en
P2093
P2860
P1433
P1476
Comparison of the capability o ...... model of Parkinson's disease.
@en
P2093
Alfred I Geller
Lingxin Kong
Qingsheng Gao
Xiaodan Wang
Xiu-gui Lu
P2860
P304
P356
10.1016/J.BRAINRES.2005.05.072
P407
P577
2005-08-01T00:00:00Z